JP2017536369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536369A5 JP2017536369A5 JP2017527260A JP2017527260A JP2017536369A5 JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5 JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5
- Authority
- JP
- Japan
- Prior art keywords
- nrc
- compound according
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 239000001301 oxygen Chemical group 0.000 claims 11
- 239000011593 sulfur Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910005965 SO 2 Inorganic materials 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims 2
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082231P | 2014-11-20 | 2014-11-20 | |
| US62/082,231 | 2014-11-20 | ||
| PCT/US2015/061463 WO2016081679A1 (en) | 2014-11-20 | 2015-11-19 | Heteroaryl compounds as irak inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536369A JP2017536369A (ja) | 2017-12-07 |
| JP2017536369A5 true JP2017536369A5 (cg-RX-API-DMAC7.html) | 2018-12-20 |
| JP6787892B2 JP6787892B2 (ja) | 2020-11-18 |
Family
ID=54705914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527260A Active JP6787892B2 (ja) | 2014-11-20 | 2015-11-19 | Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用 |
Country Status (24)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750094A (zh) | 2015-04-22 | 2021-12-07 | 里格尔药品股份有限公司 | 吡唑化合物以及制备和使用该化合物的方法 |
| WO2017144633A1 (en) * | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP4212523A1 (en) | 2016-10-26 | 2023-07-19 | Rigel Pharmaceuticals, Inc. | Pyrazole amide compounds as irak inhibitors |
| EP3532470B1 (en) | 2016-10-26 | 2022-12-07 | Rigel Pharmaceuticals, Inc. | Oxazole derivatives for use as irak inhibitors and method for their preparation |
| AU2017363313B2 (en) * | 2016-11-22 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| ES2902885T3 (es) | 2017-02-01 | 2022-03-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| JP6920467B2 (ja) * | 2017-05-02 | 2021-08-18 | コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ | ピリミジン誘導体化合物、その光学異性体、またはその薬学的に許容される塩、及びそれを有効成分として含むｔｙｒｏ３関連疾患の予防または治療用組成物 |
| JP2020525513A (ja) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 |
| PH12020550028B1 (en) | 2017-08-09 | 2024-05-24 | Denali Therapeutics Inc | Compounds, compositions and methods |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| KR20250167680A (ko) | 2018-11-30 | 2025-12-01 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20210126036A (ko) | 2019-02-13 | 2021-10-19 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| AU2020335903A1 (en) | 2019-08-30 | 2022-03-24 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP2024503300A (ja) | 2020-12-30 | 2024-01-25 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| US12357623B2 (en) | 2021-03-03 | 2025-07-15 | Rigel Pharmaceuticals, Inc. | Method for treating a disease or condition using a pyrazole compound or formulation thereof |
| WO2022217118A1 (en) * | 2021-04-09 | 2022-10-13 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| WO2022236058A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| AU2022378630A1 (en) | 2021-10-29 | 2024-05-09 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| CN116514769B (zh) * | 2022-01-21 | 2024-02-27 | 中国药科大学 | 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用 |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| JP7713603B2 (ja) | 2022-02-09 | 2025-07-25 | クアンタ セラピューティクス， インコーポレイテッド | Ｋｒａｓモジュレーターおよびその使用 |
| WO2023183377A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| EP4532494A1 (en) | 2022-05-25 | 2025-04-09 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| AU2024234154A1 (en) | 2023-03-15 | 2025-09-25 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026377A1 (en) * | 2007-08-20 | 2009-02-26 | Board Of Regents, The University Of Texas System | Metal-containing polymers and uses thereof |
| WO2009054253A1 (ja) | 2007-10-26 | 2009-04-30 | Konica Minolta Holdings, Inc. | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| BRPI0916566B8 (pt) | 2008-08-04 | 2021-05-25 | Merck Patent Ges Mit Beschraenkter Haftung | isonicotinamida fenilamina, seu uso, composição farmacêutica, e kit |
| CA2757671A1 (en) * | 2009-04-03 | 2010-10-07 | Cellzome Ag | Methods for the identification of kinase interacting molecules and for the purification of kinase proteins |
| JP2011098948A (ja) | 2009-06-25 | 2011-05-19 | Yamagata Promotional Organization For Industrial Technology | ビピリジン誘導体及びそれを含む有機エレクトロルミネッセンス素子 |
| EP2515657A4 (en) * | 2009-12-21 | 2013-07-03 | Merck Sharp & Dohme | Tyrosine kinase inhibitor |
| MX358682B (es) * | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| WO2013134415A1 (en) * | 2012-03-07 | 2013-09-12 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| US20150041789A1 (en) * | 2012-03-22 | 2015-02-12 | Konica Minolta, Inc. | Transparent electrode, electronic device, and organic electroluminescent element |
| RU2015104123A (ru) * | 2012-07-10 | 2016-08-27 | Арес Трейдинг С.А. | Производные пиримидинпиразолила |
| CA2933107C (en) | 2014-01-09 | 2022-06-21 | Merck Patent Gmbh | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
-
2015
- 2015-11-19 LT LTEP15801650.1T patent/LT3221306T/lt unknown
- 2015-11-19 JP JP2017527260A patent/JP6787892B2/ja active Active
- 2015-11-19 SI SI201531094T patent/SI3221306T1/sl unknown
- 2015-11-19 KR KR1020177015188A patent/KR20170086057A/ko not_active Ceased
- 2015-11-19 EP EP15801650.1A patent/EP3221306B1/en active Active
- 2015-11-19 HR HRP20200179TT patent/HRP20200179T1/hr unknown
- 2015-11-19 AU AU2015349899A patent/AU2015349899B9/en active Active
- 2015-11-19 DK DK15801650.1T patent/DK3221306T3/da active
- 2015-11-19 WO PCT/US2015/061463 patent/WO2016081679A1/en not_active Ceased
- 2015-11-19 KR KR1020237038922A patent/KR102683518B1/ko active Active
- 2015-11-19 RS RS20200153A patent/RS59974B1/sr unknown
- 2015-11-19 ES ES15801650T patent/ES2772133T3/es active Active
- 2015-11-19 MX MX2017006266A patent/MX375625B/es active IP Right Grant
- 2015-11-19 CA CA2964982A patent/CA2964982C/en active Active
- 2015-11-19 RU RU2017120274A patent/RU2743718C2/ru active
- 2015-11-19 NZ NZ730728A patent/NZ730728A/en not_active IP Right Cessation
- 2015-11-19 US US14/945,610 patent/US9790221B2/en active Active
- 2015-11-19 HU HUE15801650A patent/HUE047586T2/hu unknown
- 2015-11-19 SG SG11201702741SA patent/SG11201702741SA/en unknown
- 2015-11-19 PL PL15801650T patent/PL3221306T3/pl unknown
- 2015-11-19 CN CN201580073060.9A patent/CN107108561B/zh not_active Expired - Fee Related
- 2015-11-19 PT PT158016501T patent/PT3221306T/pt unknown
- 2015-11-20 AR ARP150103793A patent/AR103138A1/es unknown
-
2017
- 2017-04-05 ZA ZA2017/02402A patent/ZA201702402B/en unknown
- 2017-05-17 IL IL252346A patent/IL252346B/en active IP Right Grant
- 2017-09-12 US US15/701,842 patent/US10030013B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536369A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537501A5 (cg-RX-API-DMAC7.html) | ||
| RU2017120274A (ru) | Гетероарильные соединения в качестве ингибиторов irak и их применения | |
| JP2019527718A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505166A5 (cg-RX-API-DMAC7.html) | ||
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2378263C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| JP2012508252A5 (cg-RX-API-DMAC7.html) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2011037841A5 (cg-RX-API-DMAC7.html) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2009511490A5 (cg-RX-API-DMAC7.html) | ||
| JP2015518903A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537671A5 (cg-RX-API-DMAC7.html) | ||
| JP2018538248A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509586A5 (cg-RX-API-DMAC7.html) | ||
| JP2017511357A5 (cg-RX-API-DMAC7.html) | ||
| RU2018113451A (ru) | Гетероарильные соединения в качестве ингибиторов irak и их применение | |
| JP2017538689A5 (cg-RX-API-DMAC7.html) | ||
| EA201070871A1 (ru) | Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2015503621A5 (cg-RX-API-DMAC7.html) | ||
| JP2010528021A5 (cg-RX-API-DMAC7.html) | ||
| EA200870226A1 (ru) | Производные трициклических n-гетероарилкарбоксамидов, содержащих группу бензимидазола, их получение и применение в терапии | |
| RU2017130761A (ru) | Макроциклы пиридазинона в качестве ингибиторов irak-киназы и их применения |